The study assessed changes in symptoms [Harvey Bradshaw Index (HBI) for patients with CD or partial Mayo score (PMS) for patients with UC], systemic and gut inflammation [C-reactive protein (CRP) and fecal calprotectin (FCAL), respectively], quality of life, and levels of depression but did not assess changes in weight. The gene discussed is CRP; the disease is major depressive disorder.